{
  "drug_name": "Chloroquine",
  "url": "https://wikem.org/wiki/Chloroquine",
  "scraped_at": "2026-01-10T07:50:27.373611",
  "sections": {
    "Administration": {
      "text": "Type:\nAntimalarial\nDosage Forms:\nRoutes of Administration: Oral\nCommon Trade Names: (Aralen)",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Antimalarial",
          "url": "https://wikem.org/wiki/Antimalarial"
        }
      ]
    },
    "Adult_Dosing": {
      "text": "Most malaria-endemic areas have high rates of chloroquine resistance. Per the CDC, chloroquine-sensitive areas include: Central America west of the Panama Canal, Haiti, the Dominican Republic, and most of the Middle East. See [\nCDC malaria information by country\n] for details\nUncomplicated malaria treatment: 1000 mg PO, followed by 500mg PO at 6, 24, and 48 hours after first dose\nMalaria prophylaxis: 500 mg PO weekly beginning 1 to 2 weeks prior to travel to malarious area through 4 weeks after departure",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pediatric_Dosing": {
      "text": "Uncomplicated malaria treatment: 16.6 mg/kg PO (max 1 g), followed by 8.3 mg/kg PO at 6, 24, and 48 hours after first dose\nMalaria prophylaxis: 8.3 mg/kg PO weekly beginning 1 to 2 weeks prior to travel to malarious area through 4 weeks after departure",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Experimental_Usage": {
      "text": "COVID-19",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "COVID-19",
          "url": "https://wikem.org/wiki/COVID-19"
        }
      ]
    },
    "Special_Populations": {
      "text": "Pregnancy Rating\n: C\nLactation risk\n: Infant risk minimal\nRenal dosing:  reduce dose by 50% if CrCl < 10\nHepatic dosing: may need serum drug level monitoring as 30-50% of dose modified by liver",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Pregnancy Rating",
          "url": "https://wikem.org/wiki/Drug_Ratings_in_Pregnancy"
        },
        {
          "text": "Lactation risk",
          "url": "https://wikem.org/wiki/Lactation_risk_categories"
        }
      ]
    },
    "Contraindications": {
      "text": "Allergy to class/drug\nRetinal or visual field changes",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Adverse_Reactions": {
      "text": "",
      "subsections": {
        "Serious": {
          "text": "Prolonged QT, AV block\nHeart failure\nSJS\nNeutropenia\nExtrapyramidal disease\nSeizure\nRetinopathy",
          "tables": []
        }
      },
      "tables": [],
      "links": []
    },
    "Serious": {
      "text": "Prolonged QT, AV block\nHeart failure\nSJS\nNeutropenia\nExtrapyramidal disease\nSeizure\nRetinopathy",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Pharmacology": {
      "text": "Half-life: 1-2 months\nMetabolism: Hepatic\nExcretion: Renal, fecal",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "Mechanism_of_Action": {
      "text": "Precise mechanism unknown, action thought to be due to interaction with DNA",
      "subsections": {},
      "tables": [],
      "links": []
    },
    "See_Also": {
      "text": "Antimalarials\nMalaria",
      "subsections": {},
      "tables": [],
      "links": [
        {
          "text": "Antimalarials",
          "url": "https://wikem.org/wiki/Antimalarials"
        },
        {
          "text": "Malaria",
          "url": "https://wikem.org/wiki/Malaria"
        }
      ]
    },
    "References": {
      "text": "Lexicomp\nAkintonwa A, Gbajumo SA, and Mabadeje AF, \"Placental and Milk Transfer of Chloroquine in Humans,\" Ther Drug Monit, 1988, 10(2):147-9. [PubMed 3381230]\nAnderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. doi: 10.1002/cpt.377. [PubMed 27060684]\nAralen (chloroquine phosphate) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC: October 2018.\nAronoff GR, Bennett WM, Berns JS, et al, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 73.\nASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017.\nhttps://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6\n.\nAvina-Zubieta JA, Johnson ES, Suarez-Almazor ME, et al, “Incidence of Myopathy in Patients Treated With Antimalarials. A Report of Three Cases and a Review of the Literature,” Br J Rheumatol, 1995, 34(2):166-70. [PubMed 7704464]\nBezerra EL, Vilar MJ, da Trindade Neto PB, et al. “Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus”. Arthritis Rheum, 2005;52(10):3073-8. [PubMed 16200586]\nBoelaert JR, Yaro S, Augustijns P, Meda N, Schneider YJ, Schols D, Mols R, De Laere EA, Van de Perre P. Chloroquine accumulates in breast-milk cells: potential impact in the prophylaxis of postnatal mother-to-child transmission of HIV-1. AIDS. 2001;15(16):2205-2207. [PubMed 11684948]\nCappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64-74. doi: 10.1016/S0140-6736(08)60073-2. Review. [PubMed 18177777]\nCenters for Disease Control and Prevention (CDC), \"CDC Health Information for International Travel 2018,\" New York: Oxford University Press, 2018.",
      "subsections": {},
      "tables": [],
      "links": []
    }
  }
}